F G, M F, R G, M R. Main Determinants of Severe Neutropenia in Patients with Solid Tumors Receiving Adjuvant Chemotherapy. Iranian Journal of Blood and Cancer 2012; 5 (1) :3-7
URL:
http://ijbc.ir/article-1-388-en.html
Abstract: (10580 Views)
Background:Chemotherapy-induced neutropenia as a major toxicity of systemic chemotherapy is commonly
associated with substantial mortality and morbidity, and thus identifying its determinants is necessary. This study
was undertaken to identify main risk factors of severe neutropenia following adjuvant chemotherapy treatment in a
community-based population of patients with cancer in Semnan, Iran.
Materials and methods: This prospective study included 828 consecutive patients with histologically proven
primary or metastatic solid tumors who received chemotherapy. Demographics data, disease characteristics, and
co-morbidities (including current smoking and diabetes) were collected by face to face interviews with the patients
and also by referring to their laboratory data and files. Patients underwent complete blood count a week after the
first chemotherapy course.
Results: Based on the nadir value of the absolute neutrophil count (ANC), 30 patients (3.6%) had severe neutropenia.
Multivariable logistic regression analysis showed that advanced age (OR = 5.262, p = 0.012), and the presence of
diabetes mellitus (OR = 8.126, p = 0.015) were the main determinants for the appearance of severe neutropenia with
the presence of demographics and studied co-morbidities as confounders.
Conclusion: We identified advanced age and the presence of diabetes as the main determinants of high-grade
neutropenia in solid tumor patients receiving adjuvant chemotherapy in our study population.
Keywords: Neutropenia, solid tumor, chemotherapy.
:
Original Article |
Subject:
Pediatric Hematology & Oncology Received: 2012/04/16 | Accepted: 2012/07/13 | Published: 2013/05/30